Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.
by Heidi Hagen | August 27, 2019
Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance to cell and gene therapy -- data management. Why now? Because in advanced therapeutics, data management is patient management. To…
by Vineti | August 8, 2019
Here are a few of the notable cell therapy and gene therapy updates from the past month.
by Heidi Hagen | June 19, 2019
In cell therapy and gene therapy, in-process and final product labeling matters more to patient safety than ever before -- and it’s also more complex. We’ve been working with other industry leaders on new and updated standards for cell and gene…
- 1 (current)